Unpacking Trump’s executive order on drug pricing, with Alice Valder Curran

President Donald Trump’s April 15th executive order, “Lowering Drug Prices by Once Again Putting Americans First”, contained a smorgasbord of policy proposals targeting a variety of industry stakeholders.

But how much legal force do these different elements have, and what are the concrete takeaways for pharma? To answer these questions and more, host Jonah Comstock once again welcomed Hogan Lovells attorney Alice Valder Curran to the podcast to pick apart the order piece by piece.

They discuss the headline – Trump’s intention to eliminate the Inflation Reduction Act’s “pill penalty”, and talk about why the language is more ambiguous than it appears and could be good or bad news for pharma.

They also talk about PBM reform, closing 340B loopholes, and how much the Federal government can really do to promote drug importation from Canada at the state level.

Check out the podcast to learn everything you wanted to know about Trump’s Executive Order.